Fc Domain Binding Molecules for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibodies for immune cell activation and targeting face challenges related to toxicity, applicability, and producibility, and are limited in their flexibility to target multiple antigens and exploit NK or CTL functions simultaneously.
Innovation Solution
Development of an immune activating fragment crystallizable (Fc) domain binding molecule with specific amino acid substitutions that reduce binding to Fc receptors and effector functions, combined with a half-life extending Fc domain to enhance pharmacokinetics, allowing for customizable immune cell activation and targeting without self-binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibodies are designed to directly engage with target antigens and activate immune cells, then immune cell activation and target cell lysis are achieved, but toxicity and unwanted effector functions increase
Solution Approach 1:
The patent applies local quality by creating Fc domain variants with specific amino acid substitutions (e.g., L234A, L235A, P329G) that selectively reduce binding to certain Fc receptors while maintaining binding to others. This localized modification of the Fc domain allows differential effector function modulation, reducing unwanted toxicity while preserving desired immune cell activation capabilities.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying amino acid substitutions at specific positions in the Fc domain to modulate binding affinity to different Fc receptors. By changing these molecular parameters, the patent optimizes the balance between immune activation efficacy and toxicity reduction, creating a tailored effector function profile for therapeutic applications.
2Reliability
If conventional Fc domains are used in bispecific antibodies, then standard effector functions are achieved, but half-life and pharmacokinetics are suboptimal
Solution Approach 1:
The patent applies universality by designing Fc domain variants that simultaneously achieve multiple functions: reduced binding to certain Fc receptors (lowering toxicity), maintained or enhanced binding to other Fc receptors (preserving immune activation), and extended half-life through reduced FcRn binding. This multi-functional Fc domain serves as a universal platform for various bispecific antibody applications.
Solution Approach 2:
The patent utilizes composite materials by combining Fc domain variants with modified antigen-binding specificities to create bispecific antibodies with customized properties. The composite Fc domain integrates multiple amino acid substitutions that collectively provide tailored effector functions and pharmacokinetic profiles, optimizing both safety and efficacy.
3Adaptability or versatility
If multiple bispecific antibodies targeting different antigens are developed, then coverage of multiple targets is achieved, but development complexity and production costs increase
Solution Approach 1:
The patent applies universality by creating a library of Fc domain variants with standardized, well-characterized effector function profiles. These universal Fc domains can be combined with different antigen-binding specificities to generate multiple bispecific antibodies with predictable and consistent properties, simplifying development and manufacturing across different therapeutic candidates.
Solution Approach 2:
The patent utilizes segmentation by separating the Fc domain into distinct functional modules through specific amino acid substitutions. This modular approach allows independent optimization of different effector functions (ADCC, ADCP, CDC, half-life) and enables systematic combination with various antigen-binding specificities, reducing overall development complexity.
4Object-affected harmful factors
If Fc domain variants with reduced Fc receptor binding are created, then unwanted effector functions are reduced, but binding to activating Fc receptors may be compromised
Solution Approach 1:
The patent applies local quality by introducing amino acid substitutions at specific positions (e.g., L234A, L235A) that selectively reduce binding to inhibitory or non-activating Fc receptors while preserving binding to activating Fc receptors. This localized modification strategy allows precise control over which effector functions are modulated without compromising overall Fc receptor engagement.
Solution Approach 2:
The patent utilizes parameter changes by systematically evaluating the impact of different amino acid substitutions on binding affinity to various Fc receptors. By adjusting these molecular parameters, the patent optimizes the selectivity of Fc receptor interactions, reducing unwanted effector functions while maintaining or enhancing desired immune activation capabilities.
Data Source
AI summary
The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.